A vs. B | ||
---|---|---|
IMpower133 | CASPIAN | |
Efficacy | ||
PFS (in months) | 5.2 vs. 4.3 | 5.1 vs. 5.4 |
HR (95% CI) | 0.77 (0.62–0.96) | 0.78 (0.65–0.94) |
PFS% | ||
At 6 months | 30.9% vs. 22.4% | 45% vs. 46% |
At 12 months | 12.6% vs. 5.4% | 18% vs. 5% |
OS (in months) | 12.3 vs. 10.3 | 13.0 vs. 10.3 |
HR (95% CI) | 0.76 (0.60–0.95) | 0.73 (0.59–0.91) |
OS% at 12 months | 51.7% vs. 38.2% | 54% vs. 40% |
trAEs | ||
All grades | 94.9% vs. 92.3% | 89% vs. 90% |
Grades 3–4 | 56.6% vs. 56.1% | 46% vs. 52% |
SAEs | 22.7% vs. 18.9% | 13% vs. 19% |
irAEs | ||
All grades | 39.9% vs. 24.5% | 20% vs. 3% |
Grades 3–4 | 9.1%* vs. 2.6%* | 5% vs. < 1% |